Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.
Marianne Pavel, MD
Advertisement
Articles by Marianne Pavel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
2
Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC
3
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
4
Atirmociclib Plus Fulvestrant Improves PFS in HR+/HER2– Advanced Breast Cancer
5